Market Research Future (MRFR) reveals that the sleeping bruxism treatment market 2020 can gain a growth rate of 6.7% between 2017 and 2023 (appraisal period). The global market can procure a valuation of USD 638.2 million by 2023, adds MRFR. We will provide COVID-19 impact analysis with the report, coupled with all the significant developments in the market following the coronavirus disease outbreak.
Top Drivers and Barriers
Dentists and other dental professionals are at higher risk of getting infected with SARS-CoV-2, since they are in the proximity of the patient’s respiratory system while providing healthcare. Sleep apnea is a prevalent disorder around the world, and has gained a higher traction since the novel coronavirus pandemic, given the rising cases of obesity. However, since the COVID-19 outbreak, dentists and other medical practitioners have been making extensive use of telehealth to prevent physical contact with potentially affected patients. Video conferencing and phone consultations are also proving to be quite useful following the imposition of the global lockdown. The rising trend of AI, IoT, and other advanced technologies since the pandemic has also been favorable for the sleeping bruxism treatment industry.
The global market’s strong growth can be credited to the rising prevalence of sleeping bruxism among children. Changing lifestyle in conjunction with surging stress levels and mounting number of obstructive sleep apnea are also presumed to benefit the global market. Tooth wear and headaches are caused by sleeping bruxism and are emerging as key issues among patients, even posing risk to their lives. Therefore, consideration is being given effective techniques that can help prevent these complications, such as administration of antidepressants, muscle relaxants, mouth guard and more. In a nutshell, it is expected that the rising cases of sleep bruxism will bolster the need for effective therapeutic options like mouth guard, antidepressants and muscle relaxants in the coming years, translating into market growth.
Various medications are not completely effective when it comes to treatment of sleeping bruxism, which has given rise to researches to analyze different drugs and their efficiency. Muscle relaxants, Botox injections and anxiety and stress medications are currently the top treatment options favored by dentists for treatment. Occlusal splint, which is a sleeping bruxism treatment device, is garnering high momentum in the global industry, since it facilitates muscle relaxation, provides accurate diagnostic data, regularizes periodontal fiber proprioception and protects jaws and teeth from teeth grinding. Researches and development/R&D activities paired with product range expansion are some of the key marketing strategies that are employed by reputed vendors to stay ahead of the competition.
To illustrate, in June 2020, Formlabs boosted its proprietary 3D printing resins portfolio, which has dental, engineering and healthcare applications. Some of the key dental resins in this range include Dental LT Clear, an innovative biocompatible material that helps develop occlusal guards and splints for sleeping bruxism.
The sleeping bruxism treatment industry can be categorized as type, diagnosis, treatment type, cause, patient type, and end-user.
Primary and secondary are the primary types of sleeping bruxism in the worldwide market. The biggest share in the global market since 2017 is owned by secondary bruxism, due to the rising cases of sleep disorder, high intake of medicines and drugs that cause dental problems and the surging prevalence of stressful lifestyles across the globe.
Treatment-based categories are medication and dental approaches. Dental approaches types are mouth guard and NTI-tss device, while the medication-based segments are anti-anxiety drugs, muscle relaxants and Botox injections.
The main causes bruxism identified in the market report are obstructive sleep apnea, sleep paralysis, gastroesophageal reflux disease (GERD), malocclusion, among others. The obstructive sleep apnea category is on track to hit USD 233.20 million by 2023, and procure an advancement rate of 7.0% over the conjectured period.
Pediatric and adult are the patient types mentioned in the report. Since 2017, the pediatric segment has remained ahead in the global market, as a result of the growing hyperactivity and anger issues among children, in addition to pain from teething and earache.
The Middle East and Africa or MEA, the Americas, Europe and Asia Pacific or APAC are the key regions across which the sleeping bruxism treatment market is projected to grow at varying rates during the evaluation period.
In 2017, America had seized a share of 39.1% in the global market and has remained in the lead since then. Some of the growth promoters are the mounting cases of anxiety and stress and the substantial government spending on researches. Increase in healthcare insurance schemes and the amplified demand and introduction of advanced and innovative devices in the dental industry favor the regional market. The expanding geriatric populace in the United States, Mexico and Canada is also proving to be instrumental in the market expansion.
Europe is the second most profitable market, thanks to the growing prevalence of sleeping bruxism among children and the mounting dental awareness among people. The burgeoning patient pool suffering from irregular breathing, sleep disorders and snoring also adds to the market strength in the region.
The APAC market is slated to accrue the fastest growth rate in the forthcoming years, as a result of the rising use of superior healthcare technology, rapid economic surge and the exploding population in the emerging countries. Substantial funds allocated to healthcare and the expanding pediatric population serves as growth catalysts as well. The advancing dental industry in Japan, India, China and South Korea is also fostering the market demand in the region.
A few reputed companies in the market are Dental Products LLC, Ipsen Biopharmaceuticals Inc., Ivoclar Vivadent AG, S4S Dental Laboratory, Carestream Dental, Merz Pharma GmbH & Co. KGaA, Randmark, and more.